Jeffery W. Kelly (born August 23, 1960 in Medina, New York) is an American businessman and chemist who is on the faculty of the Scripps Research Institute in La Jolla, California.
[2] He is former Dean of Graduate Studies (2000–2008) and Vice President of Academic Affairs (2000–2006) and co-Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California.
His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical and biological strategies to ameliorate diseases caused by protein misfolding and/or aggregation.
[2] Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals with Susan Lindquist in 2003,[3] Proteostasis Therapeutics, Inc. with Andrew Dillin and Richard Morimoto in 2010,[4] and Misfolding Diagnostics[5] in 2012.
[7]: 210 Tafamidis was eventually discovered by Kelly's team using a structure-based drug design strategy; the structure was first published in 2003.
[10] 2016 - Member of the American Academy of Arts and Sciences 2017 - Chemical Pioneer Award of the American Institute of Chemists 2017 - Fellow of the Royal Society of Chemistry 2017 - Fellow of the National Academy of Inventors 2022 - Breakthrough Prize in Life Sciences 2023 - Wolf Prize in Chemistry[11] 1992 Colon, W.; Kelly, J.W.
"Partial Denaturation of Transthyretin is Sufficient for Amyloid Fibril Formation In Vitro."
"Chemical Chaperones Increase the Cellular Activity of N370S β-glucosidase: A Therapeutic Strategy for Gaucher Disease " Proc.
"Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics" Science 299, 713-716.
“Context Dependent Contributions of Backbone H-Bonding to β-Sheet Folding Energetics” Nature 430, 101-105.
“Biological and Chemical Basis for Tissue Selective Amyloid Disease”Cell 121, 73-85.
.”Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases” Cell 134, 769-781.
“Protein Native State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns” Science 331, 571-575.
; Labaudiniere, R. “Tafamidis, A Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade” Proc.